GTC will spotlight DNA and RNA-based precision oncology testing, liquid biopsy applications and research across hematologic malignancies, breast cancer metastasis and CNS involvement CHICAGO, May
Authors: Vanisha Patel1,*, Maciej Kabat1, Andrew Ip2, Sukhdeep Kaur2, Hyung Chan Suh2, Christina Cho2, David Vesole2, Michele Donato2, Maher Albitar2, Scott D. Rowley2 Affiliations:1Hackensack University
Cologne, Germany and Lake Forest, CA. USA, March 18, 2025 – Labor Dr. Wisplinghoff one of Germanys largest and most renowned medical laboratories and Genomic
The research addresses the challenge of disease relapse, a primary cause of treatment failure post-hematopoietic stem cell transplantation. By employing next-generation sequencing of cfDNA to monitor donor cell chimerism and minimal residual disease (MRD) early after transplantation, the study identifies patients at increased risk of relapse. This approach allows for potential early intervention with consolidation therapy, aiming to mitigate the risk of treatment failure.
Just published in The Journal of Liquid Biopsy Liquid biopsy for evaluating mutations and chromosomal aberrations in cerebrospinal fluid from patients with primary or metastatic
Lake Forest, CA – November 13, 2024 – Genomic Testing Cooperative (GTC), a leader in advanced genomic testing, announced the launch of GTC Interpret, a
Maher Albitar, Ahmad Charifa, Sally Agersborg, Andrew Pecora, Andrew Ip, Andre Goy Abstract: Most of the current utilization of liquid biopsy (LBx) is based on
Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology. GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.
New Paper in Journal of Clinical Pathways GTC has participated in a new paper titled: Bringing Value to Health Care. Read the paper as it
CorePath Laboratories is partnering with Genomic Testing Cooperative (GTC) to enhance its next-generation sequencing (NGS) capabilities for cancer diagnostics. This collaboration combines targeted DNA and RNA profiling with other pathology testing methods, providing comprehensive evaluations of patient samples. Additionally, liquid biopsy capabilities offer a non-invasive way to monitor therapy and detect relapse.
